5.52

3.66% -0.21

After Hours: 5.54 0.02 +0.36%

Korro Bio Inc (KRRO)

Overview News Price History Discussions Forecast

Korro Bio Inc stock is traded at $5.52, with a volume of 276.30K. It is down -3.66% in the last 24 hours and down -85.51% over the past month. Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.

Previous Close:

$5.73

Open:

$5.73

24h Volume:

276.30K

Relative Volume:

0.62

Market Cap:

$51.98M

Revenue:

Net Income/Loss:

$-81.17M

P/E Ratio:

-0.5447

EPS:

-10.1344

Net Cash Flow:

$-82.84M

1W Performance:

-13.88%

1M Performance:

-85.51%

6M Performance:

-60.00%

1Y Performance:

-89.63%

1-Day Range:

$5.4201

$5.7899

1-Week Range:

$5.4201

$6.59

52-Week Range:

$5.4201

$56.04

Korro Bio Inc Stock (KRRO) Company Profile

Name

Korro Bio Inc

Sector

Healthcare (1136)

Industry

Biotechnology (635)

Phone

617-468-1999

Address

60 FIRST STREET, CAMBRIDGE

Employee

Twitter

Next Earnings Date

2024-12-08

Latest SEC Filings

KRRO's Discussions on Twitter

Compare KRRO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KRRO Korro Bio Inc	5.52	53.96M	0	-81.17M	-82.84M	-10.13
VRTX Vertex Pharmaceuticals Inc	432.17	109.05B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	784.61	82.75B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	445.24	56.78B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	917.63	56.52B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	204.51	44.58B	447.02M	-1.18B	-906.14M	-6.1812

Korro Bio Inc Stock (KRRO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-13-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Nov-13-25	Downgrade	Chardan Capital Markets	Buy → Neutral
Nov-13-25	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-13-25	Downgrade	Piper Sandler	Overweight → Neutral
Nov-13-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-13-25	Downgrade	Raymond James	Strong Buy → Mkt Perform
Nov-13-25	Downgrade	William Blair	Outperform → Mkt Perform
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight
Apr-16-25	Initiated	Chardan Capital Markets	Buy
Jan-10-25	Initiated	Oppenheimer	Outperform
Oct-21-24	Initiated	Raymond James	Strong Buy
Aug-14-24	Initiated	William Blair	Outperform
Mar-28-24	Reiterated	H.C. Wainwright	Buy
Feb-27-24	Initiated	BMO Capital Markets	Outperform
Dec-04-23	Initiated	H.C. Wainwright	Buy
Nov-29-23	Initiated	RBC Capital Mkts	Outperform
Nov-10-23	Initiated	Piper Sandler	Overweight
Feb-15-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Feb-13-23	Downgrade	Cowen	Outperform → Market Perform
Sep-22-21	Downgrade	Goldman	Buy → Neutral
Jan-27-21	Upgrade	JP Morgan	Neutral → Overweight
Dec-22-20	Initiated	B. Riley Securities	Buy
Jul-14-20	Initiated	Oppenheimer	Outperform
May-18-20	Downgrade	JP Morgan	Overweight → Neutral
Oct-28-19	Initiated	Cowen	Outperform
Oct-28-19	Initiated	Goldman	Buy
Oct-28-19	Initiated	JP Morgan	Overweight

View All

Korro Bio Inc Stock (KRRO) Latest News

Nov 25, 2025

Korro Bio, Inc. Experiences Revision in Stock Evaluation Amid Mixed Financial Performance - Markets Mojo

Nov 25, 2025

Nov 23, 2025

Korro Bio’s RNA Editing Ambitions Take A Hit After Trial Blowup - Finimize

Nov 23, 2025

Nov 19, 2025

Korro Bio downgraded to Perform from Outperform at Oppenheimer - MSN

Nov 19, 2025

What high frequency data says about Korro Bio Inc.Portfolio Profit Report & Daily Oversold Bounce Ideas - newser.com

Nov 19, 2025

Will Korro Bio Inc. stock benefit from automationBear Alert & Technical Analysis for Trade Confirmation - newser.com

Nov 19, 2025

What indicators show strength in Korro Bio Inc.Portfolio Value Report & Consistent Income Trade Recommendations - newser.com

Nov 19, 2025

Will Korro Bio Inc. stock deliver strong dividend growthPortfolio Performance Summary & Growth Focused Investment Plans - newser.com

Nov 19, 2025

What makes Korro Bio Inc. stock attractive to growth fundsJuly 2025 News Drivers & Weekly High Return Stock Forecasts - newser.com

Nov 19, 2025

Nov 18, 2025

What is the fair value of Korro Bio Inc. stock nowJuly 2025 Earnings & Reliable Volume Spike Alerts - newser.com

Nov 18, 2025

Korro Bio, Inc.Common Stock (NQ: KRRO - FinancialContent

Nov 18, 2025

Korro Bio (KRRO) Price Target Decreased by 30.76% to 66.30 - MSN

Nov 18, 2025

Nov 16, 2025

Korro Bio stock fell after missing expectations in early stage KRRO-110 trial - MSN

Nov 16, 2025

How to track smart money flows in Korro Bio Inc.July 2025 Catalysts & Community Consensus Stock Picks - newser.com

Nov 16, 2025

Why Korro Bio Inc. stock is favored by pension fundsWeekly Trend Recap & Community Trade Idea Sharing Platform - newser.com

Nov 16, 2025

Can Korro Bio Inc. stock hit record highs againWeekly Trade Summary & Real-Time Sentiment Analysis - newser.com

Nov 16, 2025

Published on: 2025-11-16 03:17:25 - newser.com

Nov 16, 2025

Nov 15, 2025

William Blair Downgrades Korro Bio (KRRO) - MSN

Nov 15, 2025

Will Korro Bio Inc. stock attract more institutional investorsPortfolio Performance Summary & Fast Moving Trade Plans - newser.com

Nov 15, 2025

Korro Bio (KRRO): Assessing Valuation After Clinical Setbacks, Layoffs, and Strategic Pivot - Yahoo Finance

Nov 14, 2025

Why Korro Bio (KRRO) Is Down 80.0% After Restructuring, Clinical Trial Miss, and CMO Resignation - simplywall.st

Nov 14, 2025